Sign up
Log in
Capricor disputes FDA post-hoc analyses of deramiocel data ahead of July 29 advisory panel
Share
Listen to the news
Capricor disputes FDA post-hoc analyses of deramiocel data ahead of July 29 advisory panel
  • Capricor issued a rebuttal to FDA briefing materials ahead of a July 29 advisory committee on its deramiocel BLA in Duchenne muscular dystrophy.
  • Management said it responded to all FDA requests and that results are governed by SAP version 3.0, finalized before unblinding.
  • It challenged FDA post-hoc analyses as based on SAP version 1.1, described as an unsigned, incomplete internal draft later made obsolete.
  • Capricor said Phase 3 HOPE-3 met its primary endpoint, PUL 2.0, with supportive cardiac function benefits.
  • Slides were posted on its website to frame the discussion for stakeholders ahead of the meeting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607271100PRIMZONEFULLFEED9798564) on July 27, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
Terms of Service·Privacy Policy·Data Disclaimer
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved